BamSEC and AlphaSense Join Forces
Learn More

Sarepta Therapeutics Inc. – Material Contracts

NASDAQ: SRPT    
Share price (9/11/26): $20.45    
Market cap (9/11/26): $2.160 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 10-Q 8 pages Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.3
from 10-Q 9 pages Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan Stock Option Award Agreement
12/34/56
EX-10.2
from 8-K 7 pages Consulting and Advisory Agreement
12/34/56
EX-10.1
from 8-K 21 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 12 pages Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 18 pages Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan
12/34/56
EX-10.3
from 10-Q 5 pages Sarepta Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.69
from 10-K 12 pages First Amendment
12/34/56
EX-10.1
from 8-K 14 pages Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan Omnibus Equity Award Agreement Notice of Omnibus Award Grant
12/34/56
EX-10.2
from 10-Q 15 pages Separation Agreement and General Release
12/34/56
EX-10.1
from 10-Q 25 pages July 16, 2025 by Email Dallan Murray [**] Re: Warn Notice, Payment in Lieu, and Offer of Severance Dear Dallan
12/34/56
EX-10.2
from 8-K 2 pages Amendment No. 3 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan
12/34/56
EX-10.1
from 8-K 2 pages Amendment No. 4 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan
12/34/56
EX-10.67
from 10-K 125 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Exclusive License and Collaboration Agreement by and Between Arrowhead Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. November 25, 2024
12/34/56
EX-10.2
from 10-Q 4 pages By Email September 16, 2024 Jpmorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5jp England Re: Supplement to Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation to Whom It May Concern
12/34/56
EX-10.1
from 10-Q 4 pages By Email September 16, 2024 Goldman Sachs & Co. LLC 200 West Street New York, Ny 10282-2198 Attention: Josh Murray, Equity Capital Markets Telephone No.: [**] Re: Supplement to Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation to Whom It May Concern
12/34/56
EX-10.1
from 8-K 1 page Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan
12/34/56
EX-10.3
from 10-Q 7 pages Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.2
from 10-Q 8 pages Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan Stock Option Award Agreement
12/34/56
EX-10.77
from 10-K 5 pages Sarepta Therapeutics, Inc. Policy for Recoupment of Incentive Compensation
12/34/56